Vanguard Global Advisers
UNCY icon

Vanguard Global Advisers’s Unicycive Therapeutics UNCY Stock Holding History

Vanguard Global Advisers’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9K Hold
7,867
– – ﹤0.01% 3166
2026
Q1 		$51.8K Buy
+7,867
New +$51.6K ﹤0.01% 3005

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Vanguard Global Advisers's UNCY Position: Q2 2026 in Review

Vanguard Global Advisers held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 7,867 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

Vanguard Global Advisers first reported a position in UNCY in Q1 2026 and has held it in 2 quarters since. The position peaked at $51.8K in Q1 2026. 78 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Vanguard Global Advisers held 7,867 shares of Unicycive Therapeutics worth $36.9K as of Q2 2026.
  • Vanguard Global Advisers left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3166 holding.
  • Vanguard Global Advisers first reported a position in Unicycive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Unicycive Therapeutics position peaked at $51.8K in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.